BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35798977)

  • 21. Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
    Chen Y; Luo L; Zheng X; Fu H; Yang X; Huang W; Chen L; Zheng Z; Zheng J; Yang T; Liu T; Hu J
    Leuk Lymphoma; 2020 Dec; 61(14):3306-3318. PubMed ID: 32820684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
    Chaubard S; Marouf A; Lavergne D; Lemonnier F; Rossignol J; Clavert A; Gressin R; Cartron G; Waultier-Rascalou A; Vargaftig J; Salles G; Bachy E; Ghesquières H; Tournilhac O; Chauchet A; Le Gouill S; Damaj G; Fornecker LM; Sibon D; Obéric L; Michot JM; Gaulard P; Hermine O; Couronné L; Jaccard A
    Br J Haematol; 2023 May; 201(4):673-681. PubMed ID: 36799516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
    Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.
    Wang L; Yang J; Wang HN; Fu RY; Liu XD; Piao YS; Wei LQ; Wang JW; Zhang L
    Theranostics; 2021; 11(2):925-940. PubMed ID: 33391513
    [No Abstract]   [Full Text] [Related]  

  • 25. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
    Wu W; Chen X; Li N; Luo Q; Zou L
    Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.
    Kim HJ; Ock CY; Kim TM; Lee SH; Lee JY; Jung SH; Cho YS; Kim M; Keam B; Kim DW; Kim IH; Heo DS
    Cancer Res Treat; 2018 Jul; 50(3):670-680. PubMed ID: 28675023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
    Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
    Front Immunol; 2022; 13():829366. PubMed ID: 35371002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.
    Liu JX; Liu X; Yang Y; Liu WP; Wang Y; He X; Zhang LL; Qu BL; Qian LT; Hou XR; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Su H; Zhang YJ; Zhu J; Qi SN; Li YX; Song YQ
    Cancer Rep (Hoboken); 2023 May; 6(5):e1800. PubMed ID: 36919649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis.
    Pokrovsky VS; Vinnikov D
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):759-768. PubMed ID: 28621166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma].
    Wan WL; Wang J; Zhu MX; Zhang W; Ke XY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):841-845. PubMed ID: 27752167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of L-asparaginase-based regimens compared to anthracycline-based regimens in newly diagnosed extranodal NK/T-cell lymphoma, nasal type: a single Mexican center experience.
    Ávila Milord AA; Aguilar Hernández MM; Demichelis Gómez R; Agreda Vásquez GP
    Blood Res; 2018 Sep; 53(3):210-217. PubMed ID: 30310787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.
    Yang Y; Zhu Y; Cao JZ; Zhang YJ; Xu LM; Yuan ZY; Wu JX; Wang W; Wu T; Lu B; Zhu SY; Qian LT; Zhang FQ; Hou XR; Li YX
    Blood; 2015 Sep; 126(12):1424-32; quiz 1517. PubMed ID: 26109206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy.
    Bi XW; Jiang WQ; Zhang WW; Huang JJ; Xia Y; Wang Y; Sun P; Li ZM
    Ann Hematol; 2015 Jul; 94(7):1175-84. PubMed ID: 25687842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
    Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Frontline Chemotherapy for Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Network Meta-Analysis.
    Luo F; Wang JN; Liu X; Wang X; Qi SN; Li YX
    J Hematol; 2023 Oct; 12(5):215-226. PubMed ID: 37936976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
    Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.